Pittsburgh center coordinating better care after acute kidney injury
The Pittsburgh Scientific and Data Research Center for the COPE-AKI Consortium (Pitt-SDRC)
This program will build and run care and medication plans to help people who survived moderate to severe sudden kidney injury avoid further kidney and heart problems.
Quick facts
| Grant type | U01 cooperative agreement |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Pittsburgh at Pittsburgh NIH-funded |
| Lab location | 1 site (Pittsburgh, United States) |
| Project ID | NIH-11134394 on NIH RePORTER |
What this research studies
If you were hospitalized with moderate (stage 2) or severe (stage 3) acute kidney injury, this Pittsburgh center will coordinate research across hospitals to improve follow-up care after discharge. The team will develop and test practical programs — such as structured clinic visits, medication plans (including decisions about RAAS blockers and SGLT2 drugs), and non-drug supports — to reduce complications and improve quality of life. They will collect and analyze health and lab data across participating sites to see which approaches lower the risk of chronic kidney disease, repeat AKI, heart problems, and death. As the Scientific and Data Research Center, the University of Pittsburgh will run the data systems and clinical trial coordination for the COPE-AKI Consortium.
Who could benefit from this research
Good fit: People recently hospitalized for stage 2 or stage 3 acute kidney injury who can attend follow-up visits and agree to share medical records and lab results.
Not a fit: Patients with only mild (stage 1) AKI, those already on long-term dialysis for end-stage kidney disease, or those unable to participate in follow-up care may not be helped by these interventions.
Why it matters
Potential benefit: Could reduce repeat kidney injury, slow progression to chronic kidney disease or dialysis, lower cardiovascular risks, and improve quality of life for survivors of serious AKI.
How similar studies have performed: Previous work shows gaps in post-AKI care and that some CKD treatments (like RAAS blockers and SGLT2 inhibitors) help chronic kidney disease, but testing how best to use these strategies after AKI is relatively new and not yet proven.
Where this research is happening
Pittsburgh, United States
- University of Pittsburgh at Pittsburgh — Pittsburgh, United States (Active)
Researchers
- Principal investigator: Abebe, Kaleab Z — University of Pittsburgh at Pittsburgh
- Study coordinator: Abebe, Kaleab Z
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.